Save $100 with a 1-month plan

We earn commissions from brands listed on this site, which influences how listings are presented.Advertising Disclosure

Best TB-500 Providers in 2026

Our top recommendations, ranked on pharmacy sourcing, provider oversight, plan pricing and access.

Last updated November 2026

Best Overall
1Rugiet logo
9.8Exceptional

Prescription TB-500 in pre-mixed sterile vials

  • Starting at $4.52/day
  • No reconstitution at home
  • Consult included, 100% online
Visit site

Save $100 with a 1-month plan

2HealthRX logo
9.3Excellent

Single-ingredient TB-500 in all 50 states

  • $129/mo on a 12-month plan
  • $99 first month
  • $199/mo month to month
3AgelessRx logo
9.2Excellent

TB-500 on an 8-week cycle with a required break

  • From $154 per vial on the 8-week plan
  • $169 for a single 4-week vial
  • Not offered to WADA-tested athletes
4Amble logo
9.0Excellent

One all-in monthly price for TB-500 injections

  • $249/mo with provider review, supplies and shipping
  • HSA/FSA eligible
  • Video visit required in only 5 states
5Live Vital logo
8.8Very good

Physician-prescribed compounded TB-500

  • $159.50/mo on 2-month billing
  • Consult available before you buy
  • Subcutaneous dosing set by your clinician
6Rx Peps Direct logo
8.6Very good

Pharmacy-direct pricing with no subscription

  • $80 per vial plus a $39 review and $15 shipping
  • Pre-reconstituted vials
  • 28 states plus DC

HIPAA Compliant · 100% Online · Licensed U.S. Providers

Seen cheaper research vials? See how they compare with Rugiet

What TB-500 is, and what it isn't

TB-500 is a synthetic, N-acetylated copy of a seven-amino-acid stretch of thymosin beta-4. That stretch, LKKTETQ, sits at positions 17 to 23 of a 43-amino-acid protein the body makes on its own. It is the region linked to actin binding, cell migration and wound healing.

TB-500 started out as a veterinary preparation. The earliest published work on it is a 2012 method for detecting it in racehorses.

It is often marketed as though it were thymosin beta-4 itself. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons treats it as a distinct fragment. The authors note that the two are frequently conflated even though no validated biologic or clinical equivalence has been shown.

The distinction matters for anyone reading about TB-500 online. A claim drawn from a thymosin beta-4 study describes a larger molecule with a different structure. It may or may not apply to the short fragment sold as TB-500, and no study has shown that it does.

Why thymosin beta-4 studies don't settle the TB-500 question

Full-length thymosin beta-4 has been tested in people for eye, skin and heart uses. One example is a small phase 2 randomized trial of thymosin beta-4 eye drops in 9 patients with severe dry eye.

Those results belong to the full protein, not to TB-500. The 2026 orthopaedic review says they cannot establish musculoskeletal efficacy or safety. It adds that direct musculoskeletal evidence is limited to lab and rodent studies.

That gap is easy to miss. Product pages often cite thymosin beta-4 trials next to TB-500 without saying they studied a different compound. When a seller points to human results, check which molecule the study actually used.

FDA's own entry for TB-500 states that the agency has no human exposure data for any route of administration.

The animal work does show a signal. In a 2026 study of repaired Achilles tendons in rats, the TB-500 group reached a significantly higher load to failure at four weeks than controls, along with better tendon structure scores.

That signal is real, but no human study has tested TB-500 itself for recovery. A provider who promises specific results is going past the evidence.

Stacking TB-500 with BPC-157

TB-500 is most often sold next to BPC-157, and sometimes premixed with it as a "Wolverine" blend.

The same 2026 rat study tested each peptide alone and the two together. The combination added no benefit over either peptide on its own.

No human data exists on the pairing.

Regulation also shapes how a stack is dispensed. HHS's October 2026 draft policy requires a single active ingredient per compounded product, which leaves premixed blends outside it. If a provider recommends both peptides, they come as two separate prescriptions.

Separate prescriptions also make it easier to see what each one contributes. A provider can start, pause or stop either peptide on its own, rather than adjusting a single mixed vial that holds both.

How TB-500 pricing works: per vial, per month, per plan

Programs in the rankings above price TB-500 in different ways, so the headline numbers are not always comparable:

  • one charges per vial and requires a break between 8-week cycles
  • one bills two months at a time
  • one charges per order, plus a review fee and shipping
  • others discount the first month and lower the rate on longer commitments

Compare cost over the full period a provider expects you to stay on treatment, not the first-month figure.

A low introductory price can rise after the first order, and a required break can lengthen the calendar time a plan covers. Fees for the review, supplies and shipping can sit outside the advertised rate. Adding these up across the whole plan gives a fairer comparison than any single monthly number.

In prescription programs, TB-500 is given by injection only. HHS's draft policy covers TB-500 acetate for subcutaneous or intramuscular use, with no oral or nasal forms.

Format varies too. Some programs ship powder for you to mix, while others ship pre-reconstituted liquid. Powder means drawing water, mixing and measuring each dose yourself, which adds room for error. Liquid removes those steps but needs refrigeration and has a limited shelf window once mixed, so ask how long a vial lasts after opening. Rugiet ships pre-mixed sterile vials only, starting at $4.52 a day.

From withdrawn nomination to draft policy: TB-500 and the FDA

TB-500 is not approved by FDA for any use. Its status under compounding policy has shifted in a short span, and each step has a specific, limited meaning:

  • Before 2026. FDA listed TB-500 in Category 2 of its interim compounding policy. Its current list places "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in the table of substances whose nominations were withdrawn. FDA's note cites possible immunogenicity, aggregation and peptide impurities, and says the agency has no human exposure data for it. (FDA bulk substances page)
  • July 23, 2026. FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding TB-500 to the 503A bulks list. The vote is advisory. (FDA PCAC meeting page)
  • October 30, 2026. HHS published a draft enforcement discretion policy covering TB-500 acetate in subcutaneous or intramuscular injections. Pharmacies must meet ten conditions, among them a single active ingredient and adverse event reporting. Comments closed November 13, 2026. HHS says the policy is not binding and may be revisited. (Federal Register 2026-22192)

Enforcement discretion is a statement about where HHS will focus, not an approval. The regulated route remains a single-ingredient prescription filled by a licensed U.S. pharmacy.

Cancer history, drug testing and other reasons to skip TB-500

Reported side effects include injection-site irritation, nausea, headache, fatigue and lightheadedness.

Large human safety studies of TB-500 do not exist, so uncommon effects are not well described. That makes the screening conversation with a provider more important, not less. Three groups in particular should skip it or raise it with a provider before starting:

  • Drug-tested athletes. WADA's 2026 Prohibited List bans thymosin beta-4 and its derivatives at all times under section S2, and names TB-500 directly.
  • A history of cancer. The beta-thymosin family, which includes thymosin beta-4, is studied for its role in cell migration and tumor metastasis. That is a theoretical reason to talk with a provider first. There is no human data on TB-500 either way.
  • Pregnancy or breastfeeding. There is no data.

What a "research use only" TB-500 vial leaves out

Rugiet vs research-use-only TB-500 sellers
FeatureRugietPrism LabsTrue Research Labs
ProductPrescription TB-500TB-500TB-500
What the seller says about human usePrescribed by a licensed provider"Research use only""Not intended for human consumption"
Licensed provider reviews your health historyYesNoNo
Dispensed by a pharmacy on a prescriptionYesNoNo
Pre-mixed sterile vial, no mixing at homeYesNoNo

Research vials cost less per vial. What that price skips is the medical side of the transaction:

  • no prescriber
  • no patient-specific dispensing
  • no pharmacy accountability
  • quality resting on the seller's own test results

A seller's label is also a signal of intent. Wording such as "research use only" tells buyers the product was not made or packaged for a person to inject, and it shifts every question about purity, sterility and dosing back onto the buyer.

A 2026 sports medicine review describes a "gray market" of unapproved peptides operating largely outside regulatory oversight. The authors say rigorous human safety data are scarce and that the potential for serious harm is real.

HHS's draft policy reaches only licensed pharmacies and physicians compounding against a patient-specific prescription. Research-use-only sellers are not covered by it.

Rugiet prescribes TB-500 after an online consultation, as pre-mixed injectable vials compounded at licensed U.S. pharmacies.

Medical disclaimer: This content is for informational purposes only and is not medical advice. It does not replace a consultation with a licensed healthcare provider. Talk to a provider before starting TB-500 or any other treatment.

Sources

  1. Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. Published online October 27, 2026.
  2. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69.
  3. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496.
  4. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837.
  5. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935.
  6. Sribenja S, Wongkham S, Wongkham C, et al. Roles and mechanisms of β-thymosins in cell migration and cancer metastasis: an update. Cancer Invest. 2013;31(2):103-110.
  7. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; Notice of Availability. Federal Register. October 30, 2026. Document 2026-22192.
  8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
  9. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.
  10. World Anti-Doping Agency. 2026 Prohibited List.

Rugiet TB-500 is a compounded drug product and requires a prescription. Compounded drugs are not approved by FDA and do not undergo review or verification by FDA for safety, effectiveness, or quality. Prescriptions require an online consultation with a licensed provider who will determine if a prescription is medically appropriate. Individual results may vary. Offered as part of a recurring subscription. Additional terms apply. Visit rugiet.com for details and important safety information. Pricing and product details for third-party brands were verified in November 2026 and may change. Ratings reflect our editorial assessment.